Hims & Hers Stock Plunges 11% After It Cuts Its Earnings Outlook

Sales rose 49%, but the telehealth company's margin shrank and it posted a $33 million net loss.

Share
Hims & Hers Stock Plunges 11% After It Cuts Its Earnings Outlook

Hims & Hers Health, which connects customers with licensed healthcare providers through a telehealth platform, plunged 11.16% to $20.38 in Tuesday trading, as of 9:55 AM ET, erasing $597 million in market value after Monday's earnings outlook cut. The retreat came despite third-quarter sales growth of 49%.

More Sales, Less Retained

Hims & Hers lowered its full-year forecast for adjusted earnings before interest, taxes and depreciation—a measure that also excludes specified other costs—in its Monday post-close SEC filing. It now expects $257 million–$277 million, compared with its previous range of $275 million–$325 million.

The third quarter brought $890.4 million in sales. A $33 million net loss accompanied a margin decline: after product and service costs, 57% of revenue remained versus 74% previously. Growing revenue and a smaller retained share accompanied the reduced earnings forecast.

A Slide Already Underway

Tuesday's decline put Hims & Hers on pace for its second drop of 10% or more this month. At Monday's close, the stock was down 29% year-to-date, while the S&P 500 had gained 10%. Shares had also lost 26% over the previous month before Tuesday's session.

The company is changing its weight-loss business, shifting toward FDA-approved branded medicines and away from compounded alternatives. It is also expanding internationally by buying local digital-health platforms.

Weight loss is one part of a platform that also connects customers with providers for sexual health, hair loss, hormone health, dermatology and mental health. Customers order through websites and mobile apps, with many treatments sold through recurring subscriptions; the company's own pharmacies fill most prescriptions.

Hims & Hers also offers laboratory testing and over-the-counter health, skincare and supplement products. Its platform serves the United States, Canada, the United Kingdom and European Union markets including Germany, Ireland, France and Spain. Retail partnerships provide another route to customers, both online and in stores.

Hims & Hers plans to launch Peptides+ by November's end. Chief Financial Officer Yemi Okupe said peptide revenue will not be material in the fourth quarter.

Sources

More on Hims & Hers Health

All Hims & Hers Health (HIMS) coverage →